Evidence map›Paper›PMID 39008006›Full record

ReviewEuropean journal of drug metabolism and pharmacokinetics2024

Drug Interactions between Traditional Chinese Medicines and Cardiovascular Drugs.

Qi Shen, Wenxuan Chen, Wei Wang, Shuyue Kang, Yuxin Du, Jiaxi Shi, Limei Yao, Weirong Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of drug metabolism and pharmacokinetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qi ShenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Wenxuan ChenScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Wei WangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Shuyue KangScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Yuxin DuScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Jiaxi ShiThe First School of clinical medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China.
Limei YaoSchool of TCM Healthcare, Guangdong Food and Drug Vocational College, Guangzhou, 510520, Guangdong, China. yaolm2000@126.com.
Weirong LiScience and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, Guangdong, China. liwr@gzucm.edu.cn.ORCID http://orcid.org/0000-0002-3878-8724

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2023A1515011835General scientific research project of Guangdong Provincial Bureau of Traditional Chinese Medicine 20231246National Natural Science Foundation of China 82074505National Natural Science Foundation of China 82374547Special projects in key fields of ordinary colleges and universities in Guangdong Province 2022ZDZX2078
6 · The paper itself

Abstract

Cardiovascular disease (CVD) is one of the leading causes of death worldwide, and its internal medicine treatments are mostly single/few-target chemical drugs. Long-term use of cardiovascular drugs for complex chronic diseases may lead to serious adverse drug reactions. Traditional Chinese medicine (TCM) has been used to treat heart diseases for thousands of years, helping to ease symptoms and prolong patients' lifespan in ancient China. TCM has the pharmacological characteristics of being multi-component, multi-target and multi-pathway, and the combined application of TCM and western medicine can be an alternative treatment for chronic and intractable diseases with high safety levels. This article reviewed the interactions and synergistic effect of TCM and cardiovascular drugs. In the treatment of arrhythmia, TCM combined with western medicine can more effectively regulate patients' cardiac electrophysiological characteristics, reduce the onsets of premature beat and heart rate variability, lower the levels of QT interval dispersion and serum inflammatory factors, alleviate clinical symptoms and TCM syndromes, and improve cardiac function with good safety levels. In the treatment of hypertension, integrative medicine can more steadily reduce blood pressure and levels of serum inflammatory factors and improve hemodynamic indexes and exercise tolerance, and it has high safety levels, especially for pregnant women. As for coronary heart disease, the combination of TCM and antiplatelet drugs may promote the absorption of each other. However, the interaction risk of pharmacokinetic mechanism between them is low at the dose of efficacy. Integrative medicine can reduce the level of N-terminal pro-brain natriuretic peptide, delay cardiac remodeling and improve heart function and quality of life for patients with heart failure with high safety levels.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesDrugs, Chinese HerbalMedicine, Chinese TraditionalAnimalsDrug InteractionsHerb-Drug InteractionsHumansCardiovascular AgentsDrugs, Chinese Herbal

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.